⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CYCN News

Cyclerion Therapeutics, Inc. Common Stock

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression